OXFORD BIODYNAMICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.5 GBX | -5.56% |
|
-8.50% | -69.64% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patientâs therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.
Calendar
2024-05-27
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -69.64% | 22.63M | |
| +0.82% | 43.84B | |
| +4.60% | 41.68B | |
| +45.32% | 41.25B | |
| -10.92% | 27.04B | |
| +7.26% | 25.53B | |
| -25.68% | 18.18B | |
| -3.91% | 12.29B | |
| +25.15% | 12.29B | |
| +6.67% | 11.15B |
- Stock Market
- Equities
- OBD Stock
- News Oxford BioDynamics Plc
- Oxford Biodynamics : Enters Supply, Resale Deal with Agilent Technologies
